Type 1 Diabetes TrialNet, supported by the National Institutes of Health and other funding agencies, is an international consortium of researchers dedicated to the study, prevention, and early treatment of Type 1 diabetes. Since inception, Type 1 Diabetes TrialNet has screened more than 100,000 people for Type 1 diabetes risk.
The mission of the University of Florida TrialNet team is to identify family members at risk, and evaluate promising new therapies to prevent, slow or reverse the progression of the disease. The Pathway to Prevention study offers a blood test that can identify the risk for Type 1 diabetes up to 10 years before symptoms actually appear. UF TrialNet researches have screened more than 3,200 participants in this study, with the hopes of reducing complications and helping countless others at risk for Type 1 diabetes.